Pharmaceuticals News and Research

RSS

APP to commence marketing Letrozole Tablets for breast cancer in the U.S.

Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that APP Pharmaceuticals will immediately begin marketing Letrozole Tablets in the U.S., after the U.S. Food and Drug Administration granted approval to market the breast cancer treatment medication to Fresenius Kabi Oncology Limited.

7 Jun 2011

VentiRx presents VTX-2337 Phase 1 trial results against advanced solid tumors at ASCO 2011

VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 agonists for the treatment of cancer, respiratory and autoimmune diseases, today announced the presentation of results from a Phase 1 clinical trial of VTX-2337, a selective TLR8 agonist in patients with advanced solid tumors. Data were presented at the American Society of Clinical Oncology Annual Meeting in Chicago, IL.

7 Jun 2011

Crucell, GSK and PATH MVI partner to develop second-generation vaccine against malaria

The PATH Malaria Vaccine Initiative (MVI) announced today that it has entered into a collaboration with Dutch biopharmaceutical company Crucell N.V. and GlaxoSmithKline.

7 Jun 2011

Tragara's apricoxib-erlotinib Phase 2 study data on non-small cell lung cancer presented at ASCO 2011

Tragara Pharmaceuticals, Inc. announced today that apricoxib in combination with erlotinib demonstrated significant and consistent clinical benefit over erlotinib alone in a clinically relevant subset of biomarker-selected patients with non-small cell lung cancer (NSCLC) who had previously failed a platinum-containing regimen for advanced disease.

7 Jun 2011

Teva's lipegfilgrastim-pegfilgrastim comparative Phase III study in breast cancer meets primary endpoint

Teva Pharmaceutical Industries Ltd. announced today that lipegfilgrastim achieved its primary endpoint of reducing the duration of severe neutropenia in a Phase III study designed to evaluate the efficacy and safety of lipegfilgrastim (XM22) compared to pegfilgrastim (Amgen's Neulasta™).

7 Jun 2011

Thermo Fisher Scientific unveils three new mass spectrometry products at 59th Annual ASMS Conference

Thermo Fisher Scientific Inc., the world leader in serving science, introduced three breakthrough instruments that take mass spectrometry (MS) analysis to new levels of performance in resolution, speed, sensitivity and accuracy. The new instruments were unveiled at the 59th Annual ASMS Conference on Mass Spectrometry and Allied Topics, being held June 5-9 at the Colorado Convention Center.

From Thermo Fisher Scientific Inc. 7 Jun 2011

Actavis receives final FDA approval for Zolpidem ER Tablets

Actavis, an international generic pharmaceuticals company, today announced that it has received final approval from the US Food & Drug Administration to market Zolpidem Tartrate Extended-Release Tablets USP, 12.5 mg CIV. Distribution of the product has commenced.

7 Jun 2011

Positive results from RXi NeuVax Phase 2 trial on breast cancer presented at ASCO 2011

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics, announced updated data from its Phase 2 clinical trial of NeuVax at the American Society of Clinical Oncology (ASCO) annual meeting.

7 Jun 2011

Positive results from Celator CPX-351 Phase 2b study on acute myeloid leukemia presented at ASCO

Celator Pharmaceuticals today announced positive clinical results in elderly patients with newly-diagnosed secondary acute myeloid leukemia (sAML) treated with CPX-351 Liposome Injection.

7 Jun 2011

AstraZeneca receives AmeriCares' Power of Partnership Award for global health programs

AmeriCares has awarded its annual Power of Partnership Award to AstraZeneca for its outstanding commitment to increasing access to health care for people in need both here at home and throughout the developing world.

7 Jun 2011

PATH malaria vaccine initiative to collaborate with GSK and Crucell in development of 2nd-generation malaria vaccine

The PATH Malaria Vaccine Initiative (MVI) announced today that it has entered into a collaboration with Dutch biopharmaceutical company Crucell N.V. and GlaxoSmithKline (GSK). This collaboration is aimed at developing a second-generation vaccine against malaria—a deadly disease that kills close to 800,000 people annually, most of them young children under age five in Africa. MVI drives the development of malaria vaccines by joining its scientific, managerial, and field expertise with companies, universities, and governments to test potential malaria vaccines and invest in those with the most promise.

6 Jun 2011

Trifunctional antibody Catumaxomab triggers vaccination effect against cancer

TRION Pharma GmbH has announced that the results from two different studies demonstrate catumaxomab’s capacity to activate the immune system in a way that can otherwise only be achieved through vaccination. The data were obtained by two independent research teams using catumaxomab in malignant ascites and gastric cancer, respectively. The results were recently presented at the annual meeting of the American Society of Clinical Oncology (ASCO).

6 Jun 2011

Gleevec shows significant overall survival benefit for patients w/ GIST after 3 years of adjuvant treatment vs. 1 year

Novartis announced new data today showing a significant improvement in both recurrence-free survival and overall survival for patients taking Gleevec® (imatinib mesylate)* tablets for three years after surgery to remove KIT (CD117)-positive gastrointestinal stromal tumors (KIT+ GIST) compared to one year of treatment. These data will be presented at the 47th American Society of Clinical Oncology (ASCO) plenary session on Sunday, June 5.

6 Jun 2011

Encouraging data from Cylene CX-4945 Phase I dose-escalation trial presented at ASCO 2011

Cylene Pharmaceuticals, Inc. today announced the presentation of encouraging data from an ongoing Phase I dose-escalation trial of CX-4945 in patients with solid tumors at the 2011 American Society of Clinical Oncology (ASCO) annual meeting held on June 4-8 in Chicago, IL.

6 Jun 2011

Waters introduces SYNAPT G2-S at 59th ASMS Conference on Mass Spectrometry

Waters Corporation today introduced the SYNAPT® G2-S High Definition Mass Spectrometer, representing a significant step forward in performance for High Definition Mass Spectrometry. The SYNAPT G2-S incorporates both high-sensitivity Waters StepWave™ ion transfer optics and Triwave® ion mobility technologies along with a suite of new informatics tools to take qualitative and quantitative high resolution performance to a new level.

6 Jun 2011

Several drug makers plan to lower prices of vaccines for GAVI purchase

Several pharmaceutical companies have pledged to lower the prices of vaccines against childhood illnesses ahead of the GAVI Alliance conference in London next week, the Guardian reports (Quinn, 6/6).

6 Jun 2011

Constellation raises $15M in Series B extension financing

Constellation Pharmaceuticals, Inc., a leading biopharmaceutical company in the field of epigenetics, today announced that it has raised $15 million in a Series B extension financing. All major current investors participated in the round, including Third Rock Ventures, The Column Group, Venrock Associates, SR One and Altitude Life Science Ventures.

6 Jun 2011

Amylin's metreleptin clinical study data on partial lipodystrophy presented at ENDO 2011

Amylin Pharmaceuticals, Inc. today announced results from a study that showed treatment with metreleptin, an investigational treatment that is an analog of the human hormone leptin, improved diabetes and lipid control in patients with partial lipodystrophy.

6 Jun 2011

Global gene therapy market to reach $300 million by 2015

The global gene therapy market is expected to grow to over $300 million by 2015, according to a new report available on companiesandmarkets.com. The gene therapy market will grow further driven by the human genome project, the increasing incidence of cancer and other critical diseases.

6 Jun 2011

FDA accepts Sunovion ciclesonide HFA nasal aerosol NDA for review

Sunovion Pharmaceuticals Inc. today announced that the New Drug Application (NDA) submitted for ciclesonide nasal aerosol in a hydrofluoroalkane (HFA) formulation has been accepted by the U.S. Food and Drug Administration.

6 Jun 2011

Pharmaceuticals News and Research

APP to commence marketing Letrozole Tablets for breast cancer in the U.S.

VentiRx presents VTX-2337 Phase 1 trial results against advanced solid tumors at ASCO 2011

Crucell, GSK and PATH MVI partner to develop second-generation vaccine against malaria

Tragara's apricoxib-erlotinib Phase 2 study data on non-small cell lung cancer presented at ASCO 2011

Teva's lipegfilgrastim-pegfilgrastim comparative Phase III study in breast cancer meets primary endpoint

Thermo Fisher Scientific unveils three new mass spectrometry products at 59th Annual ASMS Conference

Actavis receives final FDA approval for Zolpidem ER Tablets

Positive results from RXi NeuVax Phase 2 trial on breast cancer presented at ASCO 2011

Positive results from Celator CPX-351 Phase 2b study on acute myeloid leukemia presented at ASCO

AstraZeneca receives AmeriCares' Power of Partnership Award for global health programs

PATH malaria vaccine initiative to collaborate with GSK and Crucell in development of 2nd-generation malaria vaccine

Trifunctional antibody Catumaxomab triggers vaccination effect against cancer

Gleevec shows significant overall survival benefit for patients w/ GIST after 3 years of adjuvant treatment vs. 1 year

Encouraging data from Cylene CX-4945 Phase I dose-escalation trial presented at ASCO 2011

Waters introduces SYNAPT G2-S at 59th ASMS Conference on Mass Spectrometry

Several drug makers plan to lower prices of vaccines for GAVI purchase

Constellation raises $15M in Series B extension financing

Amylin's metreleptin clinical study data on partial lipodystrophy presented at ENDO 2011

Global gene therapy market to reach $300 million by 2015

FDA accepts Sunovion ciclesonide HFA nasal aerosol NDA for review

Pittcon Highlights: Pharmaceutical & Biologic eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence